Dual inhibition of cannabinoid CB₁ receptor and inducible NOS attenuates obesity-induced chronic kidney disease.

ABSTRACT:

Background and purpose

Obesity, an important risk factor for developing chronic kidney disease (CKD), affects the kidneys by two main molecular signalling pathways: the endocannabinoid/CB₁ receptor system, whose activation in obesity promotes renal inflammation, fibrosis, and injury, and the inducible NOS (iNOS), which generates ROS resulting in oxidative stress. Hence, a compound that inhibits both peripheral CB₁ receptors and iNOS may serve as an effective therapeutic agent against obesity-induced CKD.

Experimental approach

Here, we describe the effect of a novel peripherally restricted, orally bioavailable dual CB₁ receptor/iNOS antagonist, MRI-1867 (3 mg·kg^-1 ), in ameliorating obesity-induced CKD, and compared its metabolic an

SUBMITTER: Udi S 

PROVIDER: S-EPMC6976880 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature